Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s disease, diabetic neuropathy, glaucoma, viral infections, chemotherapy-induced peripheral neuropathy and stroke, among others.

Apex Bioscience Inc. has presented phosphodiesterase PDE4 and cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A; PDE5) inhibitors reported to be useful for the treatment of cancer, chronic obstructive pulmonary disease (COPD), heart failure, hepatic fibrosis, inflammatory bowel disease, rheumatoid arthritis, idiopathic pulmonary fibrosis and Alzheimer’s disease, among others.

Tahrget Therapeutics Ltd. has patented substituted adefovir compounds acting as viral DNA polymerase inhibitors that are potentially useful for the treatment of Epstein-Barr virus infections.

Sunrock Biopharma SL has disclosed antibody-drug conjugates (ADCs) comprising an antibody targeting C-C chemokine receptor type 9 (CCR9) linked to camptothecin derivatives through a linker found to be potentially useful for the treatment of cancer.

Sitala Bio Ltd. has divulged complement factor B (CFB) inhibitors reported to be useful for the treatment of cancer, autoimmune and metabolic disease, eye, dermatological, respiratory, cardiovascular and renal disorders, among others.

Shanghai Zheye Biotechnology LLC has prepared and tested new phenylpropionic acid derivatives acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors that are potentially useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis.

Beta Pharma Inc. has disclosed antibody-drug conjugates consisting of humanized monoclonal antibody trastuzumab targeting receptor tyrosine-protein kinase erbB-2 (erbB2; HER2) covalently linked to cytotoxic drug through a cleavable linker reported to be useful for the treatment of cancer.

Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has reported GTPase KRAS (G12D mutant) inhibitors found to be useful for the treatment of non-small-cell lung and pancreatic cancer.

Insilico Medicine Inc. has patented cyclin-dependent kinase (CDK) inhibitors, particularly CDK2/cyclin E1 and/or and CDK4/cyclin D3, reported to be useful for the treatment of cancer.

Shanghai Qilu Pharmaceutical Research Development Centre Ltd. has identified soluble guanylate cyclase (sGC) activators that are potentially useful for the treatment of chronic kidney disease and diabetic nephropathy.